PAP
UTHR icon

Persistent Asset Partners’s United Therapeutics UTHR Stock Holding History

Persistent Asset Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51
Closed -$5.62K – 916
2026
Q1 		$5.62K Buy
+51
New +$25.4K ﹤0.01% 295

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Persistent Asset Partners's UTHR Position: Q2 2026 in Review

Persistent Asset Partners increased its United Therapeutics (UTHR) stake by 103% in Q2 2026, buying an estimated $3.99M and bringing the position to 13,981 shares worth $7.58M. The position accounts for 2.26% of the portfolio, ranked #6.

Persistent Asset Partners first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Persistent Asset Partners held 13,981 shares of United Therapeutics worth $7.58M as of Q2 2026.
  • Persistent Asset Partners bought 7,079 United Therapeutics shares in Q2 2026, an estimated $3.99M.
  • United Therapeutics made up 2.26% of Persistent Asset Partners's portfolio in Q2 2026, its #6 holding.
  • Persistent Asset Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.